Global Information
회사소개 | 문의 | 비교리스트

세계의 혈우병 시장 : 규모, 점유율, 동향 분석 - 종류별(혈우병 A, 혈우병 B, 혈우병 C), 시술별(온디맨드 보충요법, 정기적 보충요법), 치료법별(보충요법, 유전자 치료), 부문별 예측(2020-2027년)

Hemophilia Market Size, Share & Trends Analysis Report By Type (Type A, Type B, Type C), By Treatment (On-demand, Prophylaxis), By Therapy (Replacement Therapy, Gene Therapy), By Region, And Segment Forecasts, 2020 - 2027

리서치사 Grand View Research, Inc.
발행일 2020년 03월 상품 코드 368045
페이지 정보 영문 90 Pages
가격
US $ 5,950 ₩ 7,206,000 Unprintable PDF by E-mail (Single User License)
US $ 6,950 ₩ 8,417,000 Printable PDF by E-mail (5-User License)
US $ 8,950 ₩ 10,839,000 Printable PDF by E-mail (Enterprise License)


세계의 혈우병 시장 : 규모, 점유율, 동향 분석 - 종류별(혈우병 A, 혈우병 B, 혈우병 C), 시술별(온디맨드 보충요법, 정기적 보충요법), 치료법별(보충요법, 유전자 치료), 부문별 예측(2020-2027년) Hemophilia Market Size, Share & Trends Analysis Report By Type (Type A, Type B, Type C), By Treatment (On-demand, Prophylaxis), By Therapy (Replacement Therapy, Gene Therapy), By Region, And Segment Forecasts, 2020 - 2027
발행일 : 2020년 03월 페이지 정보 : 영문 90 Pages

세계의 혈우병(Hemophilia) 시장을 조사했으며, 시장 개요, 종류·시술·치료법·지역별 시장 규모 추정과 예측, 시장 성장 촉진요인 및 저해요인 분석, 시장 점유율, 시장 기회, 경쟁 상황, 주요 기업 개요 등의 정보를 제공합니다.

목차

제1장 조사 방법과 범위

  • 시장 세분화와 범위
  • 정보 조달
  • 정보 분석
  • 시장 구성과 데이터 가시화
  • 데이터 검증과 공개

제2장 주요 요약

  • 시장 전망
  • 시장 전망 : 부문별
  • 경쟁 분석

제3장 시장 변수, 동향, 범위

  • 시장 전망
  • 침투 및 성장 전망
  • 파이프라인 분석 : 임상 단계별
  • 이용자 관점 분석
  • 주요 최종사용자 : 제품별, 지역/국가별
  • 규제 체계
  • 시장 역학
  • 시장 분석 툴

제4장 세계의 혈우병 시장 분석 : 종류별

  • 정의와 범위
  • 시장 점유율 분석 : 종류별(실적치·예측치)
  • 부문 대시보드
  • 세계의 혈우병 시장 : 종류별
  • 시장 규모 추정과 예측 : 종류별
    • 혈우병 A
    • 혈우병 B
    • 혈우병 C
    • 기타

제5장 세계의 혈우병 시장 분석 : 치료법별

  • 정의와 범위
  • 시장 점유율 분석 : 치료법별(실적치·예측치)
  • 부문 대시보드
  • 세계의 혈우병 시장 : 치료법별
  • 시장 규모 추정과 예측 : 치료법별
    • 보충요법
    • 면역관용요법
    • 유전자 치료

제6장 세계의 혈우병 시장 분석 : 시술별

  • 정의와 범위
  • 시장 점유율 분석 : 시술별(실적치·예측치)
  • 부문 대시보드
  • 세계의 혈우병 시장 : 시술별
  • 시장 규모 추정과 예측 : 시술별
    • 온디멘드 보충요법(출혈시 보충요법)
    • 정기적 보충요법

제7장 세계의 혈우병 시장 분석 : 지역별

  • 정의와 범위
  • 시장 점유율 분석 : 지역별(실적치·예측치)
  • 부문 대시보드
  • 시장 현황
  • 시장 점유율과 주요 기업 : 지역별
  • SWOT 분석 : 지역별
  • 시장 규모 추정과 예측 : 지역별
    • 북미
    • 유럽
    • 아시아태평양
    • 라틴아메리카
    • 중동 및 아프리카

제8장 경쟁 분석

  • 주요 진출 기업의 최근 동향과 영향 분석
  • 기업 구분(이노베이터, 마켓 리더, 신흥 기업)
  • 벤더 상황
  • 공개회사
  • 민간기업
  • 공급업체 순위
  • 주요 기업 개요
    • Novo Nordisk
    • Biogen.
    • Chugai Pharmaceutical
    • Bayer Healthcare
    • Pfizer.
    • Shire Plc
    • Baxalta(Baxter Healthcare)
    • CSL Behring.
    • Octapharma

제9장 KOL(Key Opinion Leader)의 해설

제10장 제안

KSM 19.08.06

이 페이지에 게재되어 있는 내용은 최신판과 약간 차이가 있을 수 있으므로 영문목차를 함께 참조하여 주시기 바랍니다. 기타 자세한 사항은 문의 바랍니다.

List of Tables

  • TABLE 1 List of Abbreviation
  • TABLE 2 North America Hemophilia Market, By Country, 2016 - 2027 (USD Million)
  • TABLE 3 North America Hemophilia Market, By Type, 2016 - 2027 (USD Million)
  • TABLE 4 North America Hemophilia Market, By Treatment, 2016 - 2027 (USD Million)
  • TABLE 5 North America Hemophilia Market, By Therapy, 2016 - 2027 (USD Million)
  • TABLE 6 U.S. Hemophilia Market, By Type, 2016 - 2027 (USD Million)
  • TABLE 7 U.S. Hemophilia Market, By Treatment, 2016 - 2027 (USD Million)
  • TABLE 8 U.S. Hemophilia Market, By Therapy, 2016 - 2027 (USD Million)
  • TABLE 9 Canada Hemophilia Market, By Type, 2016 - 2027 (USD Million)
  • TABLE 10 Canada Hemophilia Market, By Treatment, 2016 - 2027 (USD Million)
  • TABLE 11 Canada Hemophilia Market, By Therapy, 2016 - 2027 (USD Million)
  • TABLE 12 Europe Hemophilia Market, By Country, 2016 - 2027 (USD Million)
  • TABLE 13 Europe Hemophilia Market, By Type, 2016 - 2027 (USD Million)
  • TABLE 14 Europe Hemophilia Market, By Treatment, 2016 - 2027 (USD Million)
  • TABLE 15 Europe Hemophilia Market, By Therapy, 2016 - 2027 (USD Million)
  • TABLE 16 U.K. Hemophilia Market, By Type, 2016 - 2027 (USD Million)
  • TABLE 17 U.K. Hemophilia Market, By Treatment, 2016 - 2027 (USD Million)
  • TABLE 18 U.K. Hemophilia Market, By Therapy, 2016 - 2027 (USD Million)
  • TABLE 19 Germany Hemophilia Market, By Type, 2016 - 2027 (USD Million)
  • TABLE 20 Germany Hemophilia Market, By Treatment, 2016 - 2027 (USD Million)
  • TABLE 21 Germany Hemophilia Market, By Therapy, 2016 - 2027 (USD Million)
  • TABLE 22 France Hemophilia Market, By Type, 2016 - 2027 (USD Million)
  • TABLE 23 France Hemophilia Market, By Treatment, 2016 - 2027 (USD Million)
  • TABLE 24 France Hemophilia Market, By Therapy, 2016 - 2027 (USD Million)
  • TABLE 25 Italy Hemophilia Market, By Type, 2016 - 2027 (USD Million)
  • TABLE 26 Italy Hemophilia Market, By Treatment, 2016 - 2027 (USD Million)
  • TABLE 27 Italy Hemophilia Market, By Therapy, 2016 - 2027 (USD Million)
  • TABLE 28 Spain Hemophilia Market, By Type, 2016 - 2027 (USD Million)
  • TABLE 29 Spain Hemophilia Market, By Treatment, 2016 - 2027 (USD Million)
  • TABLE 30 Spain Hemophilia Market, By Therapy, 2016 - 2027 (USD Million)
  • TABLE 31 Asia Pacific Hemophilia Market, By Country, 2016 - 2027 (USD Million)
  • TABLE 32 Asia Pacific Hemophilia Market, By Type, 2016 - 2027 (USD Million)
  • TABLE 33 Asia Pacific Hemophilia Market, By Treatment, 2016 - 2027 (USD Million)
  • TABLE 34 Asia Pacific Hemophilia Market, By Therapy, 2016 - 2027 (USD Million)
  • TABLE 35 Japan Hemophilia Market, By Type, 2016 - 2027 (USD Million)
  • TABLE 36 Japan Hemophilia Market, By Treatment, 2016 - 2027 (USD Million)
  • TABLE 37 Japan Hemophilia Market, By Therapy, 2016 - 2027 (USD Million)
  • TABLE 38 China Hemophilia Market, By Type, 2016 - 2027 (USD Million)
  • TABLE 39 China Hemophilia Market, By Treatment, 2016 - 2027 (USD Million)
  • TABLE 40 China Hemophilia Market, By Therapy, 2016 - 2027 (USD Million)
  • TABLE 41 India Hemophilia Market, By Type, 2016 - 2027 (USD Million)
  • TABLE 42 India Hemophilia Market, By Treatment, 2016 - 2027 (USD Million)
  • TABLE 43 India Hemophilia Market, By Therapy, 2016 - 2027 (USD Million)
  • TABLE 44 South Korea Hemophilia Market, By Type, 2016 - 2027 (USD Million)
  • TABLE 45 South Korea Hemophilia Market, By Treatment, 2016 - 2027 (USD Million)
  • TABLE 46 South Korea Hemophilia Market, By Therapy, 2016 - 2027 (USD Million)
  • TABLE 47 Australia Hemophilia Market, By Type, 2016 - 2027 (USD Million)
  • TABLE 48 Australia Hemophilia Market, By Treatment, 2016 - 2027 (USD Million)
  • TABLE 49 Australia Hemophilia Market, By Therapy, 2016 - 2027 (USD Million)
  • TABLE 50 Latin America Hemophilia Market, By Country, 2016 - 2027 (USD Million)
  • TABLE 51 Latin America Hemophilia Market, By Type, 2016 - 2027 (USD Million)
  • TABLE 52 Latin America Hemophilia Market, By Treatment, 2016 - 2027 (USD Million)
  • TABLE 53 Latin America Hemophilia Market, By Therapy, 2016 - 2027 (USD Million)
  • TABLE 54 Mexico Hemophilia Market, By Type, 2016 - 2027 (USD Million)
  • TABLE 55 Mexico Hemophilia Market, By Treatment, 2016 - 2027 (USD Million)
  • TABLE 56 Mexico Hemophilia Market, By Therapy, 2016 - 2027 (USD Million)
  • TABLE 57 Brazil Hemophilia Market, By Type, 2016 - 2027 (USD Million)
  • TABLE 58 Brazil Hemophilia Market, By Treatment, 2016 - 2027 (USD Million)
  • TABLE 59 Brazil Hemophilia Market, By Therapy, 2016 - 2027 (USD Million)
  • TABLE 60 Argentina Hemophilia Market, By Type, 2016 - 2027 (USD Million)
  • TABLE 61 Argentina Hemophilia Market, By Treatment, 2016 - 2027 (USD Million)
  • TABLE 62 Argentina Hemophilia Market, By Therapy, 2016 - 2027 (USD Million)
  • TABLE 63 Columbia Hemophilia Market, By Type, 2016 - 2027 (USD Million)
  • TABLE 64 Columbia Hemophilia Market, By Treatment, 2016 - 2027 (USD Million)
  • TABLE 65 Columbia Hemophilia Market, By Therapy, 2016 - 2027 (USD Million)
  • TABLE 66 MEA Hemophilia Market, By Country, 2016 - 2027 (USD Million)
  • TABLE 67 MEA Hemophilia Market, By Type, 2016 - 2027 (USD Million)
  • TABLE 68 MEA Hemophilia Market, By Treatment, 2016 - 2027 (USD Million)
  • TABLE 69 MEA Hemophilia Market, By Therapy, 2016 - 2027 (USD Million)
  • TABLE 70 South Africa Hemophilia Market, By Type, 2016 - 2027 (USD Million)
  • TABLE 71 South Africa Hemophilia Market, By Treatment, 2016 - 2027 (USD Million)
  • TABLE 72 South Africa Hemophilia Market, By Therapy, 2016 - 2027 (USD Million)
  • TABLE 73 Saudi Arabia Hemophilia Market, By Type, 2016 - 2027 (USD Million)
  • TABLE 74 Saudi Arabia Hemophilia Market, By Treatment, 2016 - 2027 (USD Million)
  • TABLE 75 Saudi Arabia Hemophilia Market, By Therapy, 2016 - 2027 (USD Million)
  • TABLE 76 UAE Hemophilia Market, By Type, 2016 - 2027 (USD Million)
  • TABLE 77 UAE Hemophilia Market, By Treatment, 2016 - 2027 (USD Million)
  • TABLE 78 UAE Hemophilia Market, By Therapy, 2016 - 2027 (USD Million)

List of Figures

  • FIG. 1 Market research process
  • FIG. 2 Information procurement
  • FIG. 3 Market summary
  • FIG. 4 Market segmentation & scope
  • FIG. 5 Market size and growth prospects
  • FIG. 6 Global hemophilia market- Key market driver analysis
  • FIG. 7 Global hemophilia market - Key market restraint analysis
  • FIG. 8 Penetration & growth prospect mapping
  • FIG. 9 Global hemophilia market - Porter's analysis
  • FIG. 10 Global hemophilia market - PESTEL analysis
  • FIG. 11 Global hemophilia market type outlook key takeaways
  • FIG. 12 Global hemophilia market: Type movement analysis
  • FIG. 13 Hemophilia A market estimates, 2016 - 2027 (USD Million)
  • FIG. 14 Hemophilia B market estimates, 2016 - 2027 (USD Million)
  • FIG. 15 Hemophilia C market estimates, 2016 - 2027 (USD Million)
  • FIG. 16 Others market estimates, 2016 - 2027 (USD Million)
  • FIG. 17 Global hemophilia market treatment outlook key takeaways
  • FIG. 18 Global hemophilia market: Treatment movement analysis
  • FIG. 19 On-demand market estimates, 2016 - 2027 (USD Million)
  • FIG. 20 Prophylaxis market estimates, 2016 - 2027 (USD Million)
  • FIG. 21 Global hemophilia market therapy outlook key takeaways
  • FIG. 22 Global hemophilia market: Therapy movement analysis
  • FIG. 23 Replacement therapy market estimates, 2016 - 2027 (USD Million)
  • FIG. 24 ITI therapy market estimates, 2016 - 2027 (USD Million)
  • FIG. 25 Gene therapy market estimates, 2016 - 2027 (USD Million)
  • FIG. 26 Regional marketplace: Key takeaways
  • FIG. 27 Global hemophilia market: Regional movement analysis
  • FIG. 28 North America hemophilia market, 2016 - 2027 (USD Million)
  • FIG. 29 U.S. hemophilia market, 2016 - 2027 (USD Million)
  • FIG. 30 Canada hemophilia market, 2016 - 2027 (USD Million)
  • FIG. 31 Europe hemophilia market, 2016 - 2027 (USD Million)
  • FIG. 32 U.K. hemophilia market, 2016 - 2027 (USD Million)
  • FIG. 33 Germany hemophilia market, 2016 - 2027 (USD Million)
  • FIG. 34 France hemophilia market, 2016 - 2027 (USD Million)
  • FIG. 35 Spain hemophilia market, 2016 - 2027 (USD Million)
  • FIG. 36 Italy hemophilia market, 2016 - 2027 (USD Million)
  • FIG. 37 Asia Pacific hemophilia market, 2016 - 2027 (USD Million)
  • FIG. 38 Japan hemophilia market, 2016 - 2027 (USD Million)
  • FIG. 39 China hemophilia market, 2016 - 2027 (USD Million)
  • FIG. 40 India hemophilia market, 2016 - 2027 (USD Million)
  • FIG. 41 South Korea hemophilia market, 2016 - 2027 (USD Million)
  • FIG. 42 Australia hemophilia market, 2016 - 2027 (USD Million)
  • FIG. 43 Latin America hemophilia market, 2016 - 2027 (USD Million)
  • FIG. 44 Brazil hemophilia market, 2016 - 2027 (USD Million)
  • FIG. 45 Mexico hemophilia market, 2016 - 2027 (USD Million)
  • FIG. 46 Argentina hemophilia market, 2016 - 2027 (USD Million)
  • FIG. 47 Colombia hemophilia market, 2016 - 2027 (USD Million)
  • FIG. 48 MEA hemophilia market, 2016 - 2027 (USD Million)
  • FIG. 49 South Africa hemophilia market, 2016 - 2027 (USD Million)
  • FIG. 50 Saudi Arabia hemophilia market, 2016 - 2027 (USD Million)
  • FIG. 51 UAE market, 2016 - 2027 (USD Million)
  • FIG. 52 Strategy framework

The global hemophilia market size is expected to reach USD 18.1 billion by 2027, according to a new report by Grand View Research, Inc. It is anticipated to register a CAGR of 5.5% over the forecast period. Increasing awareness of early diagnosis and treatment coupled with supportive government policies is anticipated to boost market share over the forecast period.

For instance, the NHF (National Hemophilia Foundation) allows to find treatments for inheritable bleeding disorders and help prevent complications of these disorders through research, education, and advocacy. Their programs and initiatives are in association with the Centers for Disease Control and Prevention.

In addition, U.S. Hemophilia Treatment Center Network provides specialized healthcare centers and these offer care to address all psychological, educational, and physical needs of patients suffering from the disease. These centers currently provide care to more than 35,000 adults and children with the disease and other bleeding disorders.

The key market companies are projected to adopt strategic initiatives including geographic expansion and R&D especially in developing and underdeveloped regions, such as Middle Eastern and West African countries.

For instance, BioMarin is involved in developing Valoctocogene Roxaparvovec (BMN-270) for treating type A patients and is currently under clinical trials. Furthermore, in June 2017, the U.S. FDA accepted the investigational new drug application for Sanofi's BIVV001 based on its preclinical study results.

Rising incidence of the disease is estimated to propel hemophilia market growth over the forecast period. According to the data published by the NHF, around 20,000 individuals in U.S. are suffering from this disease. In addition, approximately 75% of people with hemophilia receive inadequate treatment or have less/ no access to treatment globally.

Further key findings from the report suggest:

Hemophilia A held the largest market share in 2019 due to its increasing prevalence worldwide

Type B is expected to be the fastest growing type over the forecast period, at a CAGR of 6.8%

On-demand dominated the treatment segment over the forecast period and is expected to contribute majority of the share in 2019

Prophylaxis is estimated to be the fastest growing segment over the forecast period

Replacement therapy was expected to be the largest segment in 2019

Gene therapy dominated the therapy segment over the forecast period owing to increasing involvement of companies to develop more gene therapy for its treatment

Increasing research and development and strategic collaborations are key strategies undertaken by major players in the market space.

Table of Contents

Chapter 1. Methodology and Scope

  • 1.1. Market segmentation & scope
  • 1.2. Information procurement
    • 1.2.1. Purchased database
    • 1.2.2. GVR's internal database
    • 1.2.3. Secondary sources & third party perspectives
    • 1.2.4. Primary research
  • 1.3. Information analysis
    • 1.3.1. Data analysis models
  • 1.4. Market formulation & data visualization
  • 1.5. Data validation & publishing

Chapter 2. Executive Summary

  • 2.1. Market Outlook
  • 2.2. Segment Outlook
  • 2.3. Competitive Insights

Chapter 3. Hemophilia Market Variables, Trends & Scope

  • 3.1. Market Lineage outlook
    • 3.1.1. Parent/ Ancillary market outlook
  • 3.2. Penetration & Growth Prospect Mapping
  • 3.3. Product Pipeline Analysis
  • 3.4. Regulation Framework
  • 3.5. Market Dynamics
    • 3.5.1. Market Driver Analysis
      • 3.5.1.1. Increasing population of newborns
      • 3.5.1.2. Favorable government initiative
      • 3.5.1.3. Rising R&D and new product development
      • 3.5.1.4. Rising adoption for prophylaxis treatment
    • 3.5.2. Market Restraint Analysis
      • 3.5.2.1. High cost associated to procure treatment
  • 3.6. Hemophilia: Market Analysis Tools
    • 3.6.1. Industry Analysis - Porter's
      • 3.6.1.1. Supplier Power: Moderate due to presence of suppliers in the market
      • 3.6.1.2. Buyer Power: Low due to high cost of the treatment
      • 3.6.1.3. Substitution Threat: High due to presence of internal substitutes
      • 3.6.1.4. Threat from new entrant: Moderate due to presence of strong global presence of existing players
      • 3.6.1.5. Competitive rivalry: High due to involvement of companies into developing novel therapies
    • 3.6.2. PESTEL Analysis
      • 3.6.2.1. Political Landscape
      • 3.6.2.2. Environmental Landscape
      • 3.6.2.3. Social Landscape
      • 3.6.2.4. Technology Landscape
      • 3.6.2.5. Legal Landscape
    • 3.6.3. Major Deals & Strategic Alliances Analysis
      • 3.6.3.1. Joint Ventures
      • 3.6.3.2. Mergers & Acquisitions
      • 3.6.3.3. Licensing & Partnership
      • 3.6.3.4. Technology Collaborations
      • 3.6.3.5. Strategic Divestments

Chapter 4. Hemophilia Market: Segment Analysis, By Type, 2016 - 2027 (USD Million)

  • 4.1. Definitions & Scope
  • 4.2. Type market share analysis, 2019 & 2027
  • 4.3. Segment Dashboard
  • 4.4. Global Hemophilia Market, By Type, 2016 to 2027
  • 4.5. Market Size & Forecasts and Trend Analyses, 2016 to 2027 for the following
    • 4.5.1. Hemophilia A
    • 4.5.2. Hemophilia B
    • 4.5.3. Hemophilia C
    • 4.5.4. Others

Chapter 5. Hemophilia market: Segment Analysis, By Treatment, 2016 - 2027 (USD Million)

  • 5.1. Definitions & Scope
  • 5.2. Treatment market share analysis, 2019 & 2027
  • 5.3. Segment Dashboard
  • 5.4. Global Hemophilia Market, By Treatment, 2016 to 2027
  • 5.5. Market Size & Forecasts and Trend Analyses, 2016 to 2027 for the following
    • 5.5.1. On- demand
    • 5.5.2. Prophylaxis

Chapter 6. Hemophilia market: Segment Analysis, By Therapy, 2016 - 2027 (USD Million)

  • 6.1. Definitions & Scope
  • 6.2. Therapy market share analysis, 2019 & 2027
  • 6.3. Segment Dashboard
  • 6.4. Global Hemophilia Market, By Therapy, 2016 to 2027
  • 6.5. Market Size & Forecasts and Trend Analyses, 2016 to 2027 for the following
    • 6.5.1. Replacement therapy
    • 6.5.2. Gene therapy
    • 6.5.3. ITI therapy

Chapter 7. Hemophilia market: Regional Market Analysis, By Region, 2016 - 2027 (USD Million)

  • 7.1. Definitions & Scope
  • 7.2. Regional market share analysis, 2019 & 2027
  • 7.3. Regional Market Dashboard
  • 7.4. Regional Market Share and Leading Players, 2019
  • 7.5. SWOT Analysis, by Factor (Political & Legal, Economic And Technological)
    • 7.5.1. North America
    • 7.5.2. Europe
    • 7.5.3. Asia Pacific
    • 7.5.4. Latin America
    • 7.5.5. Middle East & Africa
  • 7.6. Market Size, & Forecasts and Trend Analysis
  • 7.7. North America
    • 7.7.1. Market estimates and forecast, by country, 2016 - 2027 (USD Million)
    • 7.7.2. Market estimates and forecast, by type, 2016 - 2027 (USD Million)
    • 7.7.3. Market estimates and forecast, by treatment, 2016 - 2027 (USD Million)
    • 7.7.4. Market estimates and forecast, by therapy, 2016 - 2027 (USD Million)
    • 7.7.5. U.S.
      • 7.7.5.1. Market estimates and forecast, by type, 2016 - 2027 (USD Million)
      • 7.7.5.2. Market estimates and forecast, by treatment, 2016 - 2027 (USD Million)
      • 7.7.5.3. Market estimates and forecast, by therapy, 2016 - 2027 (USD Million)
    • 7.7.6. Canada
      • 7.7.6.1. Market estimates and forecast, by type, 2016 - 2027 (USD Million)
      • 7.7.6.2. Market estimates and forecast, by treatment, 2016 - 2027 (USD Million)
      • 7.7.6.3. Market estimates and forecast, by therapy, 2016 - 2027 (USD Million)
  • 7.8. Europe
    • 7.8.1. Market estimates and forecast, by country, 2016 - 2027 (USD Million)
    • 7.8.2. Market estimates and forecast, by type, 2016 - 2027 (USD Million)
    • 7.8.3. Market estimates and forecast, by treatment, 2016 - 2027 (USD Million)
    • 7.8.4. Market estimates and forecast, by therapy, 2016 - 2027 (USD Million)
    • 7.8.5. Germany
      • 7.8.5.1. Market estimates and forecast, by type, 2016 - 2027 (USD Million)
      • 7.8.5.2. Market estimates and forecast, by treatment, 2016 - 2027 (USD Million)
      • 7.8.5.3. Market estimates and forecast, by therapy, 2016 - 2027 (USD Million)
    • 7.8.6. U.K.
      • 7.8.6.1. Market estimates and forecast, by type, 2016 - 2027 (USD Million)
      • 7.8.6.2. Market estimates and forecast, by treatment, 2016 - 2027 (USD Million)
      • 7.8.6.3. Market estimates and forecast, by therapy, 2016 - 2027 (USD Million)
    • 7.8.7. France
      • 7.8.7.1. Market estimates and forecast, by type, 2016 - 2027 (USD Million)
      • 7.8.7.2. Market estimates and forecast, by treatment, 2016 - 2027 (USD Million)
      • 7.8.7.3. Market estimates and forecast, by therapy, 2016 - 2027 (USD Million)
    • 7.8.8. Italy
      • 7.8.8.1. Market estimates and forecast, by type, 2016 - 2027 (USD Million)
      • 7.8.8.2. Market estimates and forecast, by treatment, 2016 - 2027 (USD Million)
      • 7.8.8.3. Market estimates and forecast, by therapy, 2016 - 2027 (USD Million)
    • 7.8.9. Spain
      • 7.8.9.1. Market estimates and forecast, by type, 2016 - 2027 (USD Million)
      • 7.8.9.2. Market estimates and forecast, by treatment, 2016 - 2027 (USD Million)
      • 7.8.9.3. Market estimates and forecast, by therapy, 2016 - 2027 (USD Million)
  • 7.9. Asia Pacific
    • 7.9.1. Market estimates and forecast, by country, 2016 - 2027 (USD Million)
    • 7.9.2. Market estimates and forecast, by type, 2016 - 2027 (USD Million)
    • 7.9.3. Market estimates and forecast, by treatment, 2016 - 2027 (USD Million)
    • 7.9.4. Market estimates and forecast, by therapy, 2016 - 2027 (USD Million)
    • 7.9.5. China
      • 7.9.5.1. Market estimates and forecast, by type, 2016 - 2027 (USD Million)
      • 7.9.5.2. Market estimates and forecast, by treatment, 2016 - 2027 (USD Million)
      • 7.9.5.3. Market estimates and forecast, by therapy, 2016 - 2027 (USD Million)
    • 7.9.6. Japan
      • 7.9.6.1. Market estimates and forecast, by type, 2016 - 2027 (USD Million)
      • 7.9.6.2. Market estimates and forecast, by treatment, 2016 - 2027 (USD Million)
      • 7.9.6.3. Market estimates and forecast, by therapy, 2016 - 2027 (USD Million)
    • 7.9.7. India
      • 7.9.7.1. Market estimates and forecast, by type, 2016 - 2027 (USD Million)
      • 7.9.7.2. Market estimates and forecast, by treatment, 2016 - 2027 (USD Million)
      • 7.9.7.3. Market estimates and forecast, by therapy, 2016 - 2027 (USD Million)
    • 7.9.8. Australia
      • 7.9.8.1. Market estimates and forecast, by type, 2016 - 2027 (USD Million)
      • 7.9.8.2. Market estimates and forecast, by treatment, 2016 - 2027 (USD Million)
      • 7.9.8.3. Market estimates and forecast, by therapy, 2016 - 2027 (USD Million)
    • 7.9.9. South Korea
      • 7.9.9.1. Market estimates and forecast, by type, 2016 - 2027 (USD Million)
      • 7.9.9.2. Market estimates and forecast, by treatment, 2016 - 2027 (USD Million)
      • 7.9.9.3. Market estimates and forecast, by therapy, 2016 - 2027 (USD Million)
  • 7.10. Latin America
    • 7.10.1. Market estimates and forecast, by country, 2016 - 2027 (USD Million)
    • 7.10.2. Market estimates and forecast, by type, 2016 - 2027 (USD Million)
    • 7.10.3. Market estimates and forecast, by treatment, 2016 - 2027 (USD Million)
    • 7.10.4. Market estimates and forecast, by therapy, 2016 - 2027 (USD Million)
    • 7.10.5. Brazil
      • 7.10.5.1. Market estimates and forecast, by type, 2016 - 2027 (USD Million)
      • 7.10.5.2. Market estimates and forecast, by treatment, 2016 - 2027 (USD Million)
      • 7.10.5.3. Market estimates and forecast, by therapy, 2016 - 2027 (USD Million)
    • 7.10.6. Mexico
      • 7.10.6.1. Market estimates and forecast, by type, 2016 - 2027 (USD Million)
      • 7.10.6.2. Market estimates and forecast, by treatment, 2016 - 2027 (USD Million)
      • 7.10.6.3. Market estimates and forecast, by therapy, 2016 - 2027 (USD Million)
    • 7.10.7. Argentina
      • 7.10.7.1. Market estimates and forecast, by type, 2016 - 2027 (USD Million)
      • 7.10.7.2. Market estimates and forecast, by treatment, 2016 - 2027 (USD Million)
      • 7.10.7.3. Market estimates and forecast, by therapy, 2016 - 2027 (USD Million)
    • 7.10.8. Colombia
      • 7.10.8.1. Market estimates and forecast, by type, 2016 - 2027 (USD Million)
      • 7.10.8.2. Market estimates and forecast, by treatment, 2016 - 2027 (USD Million)
      • 7.10.8.3. Market estimates and forecast, by therapy, 2016 - 2027 (USD Million)
  • 7.11. Middle East and Africa
    • 7.11.1. Market estimates and forecast, by country, 2016 - 2027 (USD Million)
    • 7.11.2. Market estimates and forecast, by type, 2016 - 2027 (USD Million)
    • 7.11.3. Market estimates and forecast, by treatment, 2016 - 2027 (USD Million)
    • 7.11.4. Market estimates and forecast, by therapy, 2016 - 2027 (USD Million)
    • 7.11.5. South Africa
      • 7.11.5.1. Market estimates and forecast, by type, 2016 - 2027 (USD Million)
      • 7.11.5.2. Market estimates and forecast, by treatment, 2016 - 2027 (USD Million)
      • 7.11.5.3. Market estimates and forecast, by therapy, 2016 - 2027 (USD Million)
    • 7.11.6. Saudi Arabia
      • 7.11.6.1. Market estimates and forecast, by type, 2016 - 2027 (USD Million)
      • 7.11.6.2. Market estimates and forecast, by treatment, 2016 - 2027 (USD Million)
      • 7.11.6.3. Market estimates and forecast, by therapy, 2016 - 2027 (USD Million)
    • 7.11.7. UAE
      • 7.11.7.1. Market estimates and forecast, by type, 2016 - 2027 (USD Million)
      • 7.11.7.2. Market estimates and forecast, by treatment, 2016 - 2027 (USD Million)
      • 7.11.7.3. Market estimates and forecast, by therapy, 2016 - 2027 (USD Million)

Chapter 8. Hemophilia market - Competitive Analysis

  • 8.1. Recent developments & impact analysis, by key market participants
  • 8.2. Company/Competition Categorization (Key innovators, Market leaders, Emerging players)
  • 8.3. Public Companies
    • 8.3.1. Company market position analysis (Revenue, geographic presence, product portfolio, key serviceable industries, key alliances)
    • 8.3.2. Company Market Share/Ranking, by region
    • 8.3.3. Competitive Dashboard Analysis
  • 8.4. Private Companies
    • 8.4.1. List of key emerging companies/technology disruptors/innovators
    • 8.4.2. Regional network map
    • 8.4.3. Company market position analysis
  • 8.5. Key companies profiles
    • 8.5.1. Novo Nordisk A/S
      • 8.5.1.1. Company Overview
      • 8.5.1.2. Financial Performance
      • 8.5.1.3. Product Benchmarking
      • 8.5.1.4. Strategic Initiatives
    • 8.5.2. Shire
      • 8.5.2.1. Company Overview
      • 8.5.2.2. Financial Performance
      • 8.5.2.3. Product Benchmarking
      • 8.5.2.4. Strategic Initiatives
    • 8.5.3. Chugai Pharmaceutical Co. Ltd.
      • 8.5.3.1. Company Overview
      • 8.5.3.2. Financial Performance
      • 8.5.3.3. Product Benchmarking
      • 8.5.3.4. Strategic Initiatives
    • 8.5.4. Bayer AG
      • 8.5.4.1. Company Overview
      • 8.5.4.2. Financial Performance
      • 8.5.4.3. Product Benchmarking
      • 8.5.4.4. Strategic Initiatives
    • 8.5.5. Pfizer, Inc.
      • 8.5.5.1. Company Overview
      • 8.5.5.2. Financial Performance
      • 8.5.5.3. Product Benchmarking
      • 8.5.5.4. Strategic Initiatives
    • 8.5.6. CSL Behring
      • 8.5.6.1. Company Overview
      • 8.5.6.2. Financial Performance
      • 8.5.6.3. Product Benchmarking
      • 8.5.6.4. Strategic Initiatives
    • 8.5.7. BioMarin
      • 8.5.7.1. Company Overview
      • 8.5.7.2. Financial Performance
      • 8.5.7.3. Product Benchmarking
      • 8.5.7.4. Strategic Initiatives
    • 8.5.8. Octopharma AG
      • 8.5.8.1. Company Overview
      • 8.5.8.2. Financial Performance
      • 8.5.8.3. Product Benchmarking
      • 8.5.8.4. Strategic Initiatives
    • 8.5.9. Genzyme Corporation
      • 8.5.9.1. Company Overview
      • 8.5.9.2. Financial Performance
      • 8.5.9.3. Product Benchmarking
      • 8.5.9.4. Strategic Initiatives
    • 8.5.10. Spark Therapeutics, Inc.
      • 8.5.10.1. Company Overview
      • 8.5.10.2. Financial Performance
      • 8.5.10.3. Product Benchmarking
      • 8.5.10.4. Strategic Initiatives
Back to Top
전화 문의
F A Q